American Money Management’s Regeneron Pharmaceuticals REGN Stock Holding History

American Money Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-600	Closed	-$242K	–	75
2018 Q3	$242K	Hold	600	–	–	0.14%	69
2018 Q2	$207K	Hold	600	–	–	0.13%	71
2018 Q1	$207K	Hold	600	–	–	0.13%	70
2017 Q4	$226K	Sell	600 -150	-20%	-$60.8K	0.14%	69
2017 Q3	$335K	Hold	750	–	–	0.22%	62
2017 Q2	$368K	Sell	750 -35	-4%	-$15.3K	0.26%	59
2017 Q1	$304K	Hold	785	–	–	0.22%	62
2016 Q4	$288K	Hold	785	–	–	0.23%	64
2016 Q3	$316K	Hold	785	–	–	0.25%	62
2016 Q2	$274K	Buy	785 +25	+3%	+$9.63K	0.23%	64
2016 Q1	$274K	Hold	760	–	–	0.23%	66
2015 Q4	$413K	Hold	760	–	–	0.35%	57
2015 Q3	$354K	Buy	760 +130	+21%	+$69.8K	0.33%	60
2015 Q2	$321K	Buy	+630	New	+$307K	0.27%	62

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

American Money Management's REGN Position: Q4 2018 in Review

American Money Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2018, closing a stake of 600 shares — an estimated $242K sold.

American Money Management first reported a position in REGN in Q2 2015 and held it in 14 quarters. The position peaked at $413K in Q4 2015. 671 funds tracked by Wall St. Rank hold REGN as of Q4 2018.

American Money Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
American Money Management sold 600 Regeneron Pharmaceuticals shares in Q4 2018, an estimated $242K.
American Money Management first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 14 quarters.
American Money Management's Regeneron Pharmaceuticals position peaked at $413K in Q4 2015.
671 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2018.

Based on American Money Management's 13F filing for Q4 2018, filed 12 Feb 2019.